MX2013008185A - Compuesto de imidazo [4, 5-c] quinazolin-2-ona y su uso como inhibidor dual de cinasa pi3/mtor. - Google Patents
Compuesto de imidazo [4, 5-c] quinazolin-2-ona y su uso como inhibidor dual de cinasa pi3/mtor.Info
- Publication number
- MX2013008185A MX2013008185A MX2013008185A MX2013008185A MX2013008185A MX 2013008185 A MX2013008185 A MX 2013008185A MX 2013008185 A MX2013008185 A MX 2013008185A MX 2013008185 A MX2013008185 A MX 2013008185A MX 2013008185 A MX2013008185 A MX 2013008185A
- Authority
- MX
- Mexico
- Prior art keywords
- quinolin
- imidazo
- compound
- kinase
- dual inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un compuesto de imidazo[4,5-c]quinolin-2-ona (fórmula (I)), o una sal del mismo farmacéuticamente aceptable, que inhibe tanto PI3K como mTOR y, por lo tanto, es útil en el tratamiento de cáncer. (Ver Formula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161432958P | 2011-01-14 | 2011-01-14 | |
PCT/US2012/020897 WO2012097039A1 (en) | 2011-01-14 | 2012-01-11 | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013008185A true MX2013008185A (es) | 2013-08-21 |
Family
ID=45531593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013008185A MX2013008185A (es) | 2011-01-14 | 2012-01-11 | Compuesto de imidazo [4, 5-c] quinazolin-2-ona y su uso como inhibidor dual de cinasa pi3/mtor. |
Country Status (39)
Country | Link |
---|---|
US (2) | US8440829B2 (es) |
EP (1) | EP2663564B1 (es) |
JP (1) | JP5891247B2 (es) |
KR (1) | KR101561360B1 (es) |
CN (1) | CN103282364B (es) |
AR (1) | AR084551A1 (es) |
AU (1) | AU2012205619B2 (es) |
BR (1) | BR112013017672A2 (es) |
CA (1) | CA2824760C (es) |
CL (1) | CL2013002005A1 (es) |
CO (1) | CO6731133A2 (es) |
CR (1) | CR20130289A (es) |
CY (1) | CY1116007T1 (es) |
DK (1) | DK2663564T3 (es) |
DO (1) | DOP2013000158A (es) |
EA (1) | EA022163B1 (es) |
EC (1) | ECSP13012764A (es) |
ES (1) | ES2531891T3 (es) |
GT (1) | GT201300180A (es) |
HK (1) | HK1188454A1 (es) |
HR (1) | HRP20150135T1 (es) |
HU (1) | HUE024426T2 (es) |
IL (1) | IL227165A (es) |
JO (1) | JO3003B1 (es) |
ME (1) | ME02019B (es) |
MX (1) | MX2013008185A (es) |
MY (1) | MY164705A (es) |
PE (1) | PE20140864A1 (es) |
PL (1) | PL2663564T3 (es) |
PT (1) | PT2663564E (es) |
RS (1) | RS53828B1 (es) |
SG (1) | SG191744A1 (es) |
SI (1) | SI2663564T1 (es) |
SV (1) | SV2013004496A (es) |
TN (1) | TN2013000237A1 (es) |
TW (1) | TWI518086B (es) |
UA (1) | UA109921C2 (es) |
WO (1) | WO2012097039A1 (es) |
ZA (1) | ZA201304757B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
WO2015073804A2 (en) * | 2013-11-15 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of blocking transmission of malarial parasite |
TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
TW201703769A (zh) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | 用於癌症的組合療法 |
GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
NZ742470A (en) * | 2015-12-15 | 2019-09-27 | Lilly Co Eli | Combination therapy for cancer |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
JP6911047B2 (ja) * | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 |
MX2018013941A (es) | 2016-05-20 | 2019-03-21 | Lilly Co Eli | Terapia de combinacion con inhibidores de notch y pd-1 o pd-l1. |
WO2018017410A1 (en) | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
WO2018063873A1 (en) | 2016-09-27 | 2018-04-05 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer |
EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
EP4269594A3 (en) | 2017-02-17 | 2023-12-20 | Fred Hutchinson Cancer Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
WO2020081329A1 (en) * | 2018-10-18 | 2020-04-23 | Camp4 Therapeutics Corporation | Methods and compositions for modulating pcsk9 and angptl3 expression |
TW202134234A (zh) | 2019-12-05 | 2021-09-16 | 美商奈維特製藥公司 | 雷帕黴素類似物及其用途 |
WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
DE602004014969D1 (de) | 2003-11-21 | 2008-08-21 | Novartis Ag | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
CA2598656A1 (en) * | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
EP2356120B1 (en) | 2008-09-30 | 2016-10-12 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
EP2438063A1 (en) | 2009-06-04 | 2012-04-11 | Novartis AG | 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases |
EA020715B1 (ru) | 2009-06-04 | 2015-01-30 | Новартис Аг | ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА |
CA2766967A1 (en) * | 2009-06-30 | 2011-01-06 | Piramal Life Sciences Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
MX2013006284A (es) * | 2010-12-06 | 2013-10-28 | Piramal Entpr Ltd | Derivados sustituidos de imidazoquinolina. |
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
-
2011
- 2011-12-20 JO JOP/2011/0389A patent/JO3003B1/ar active
- 2011-12-22 AR ARP110104894A patent/AR084551A1/es unknown
- 2011-12-23 TW TW100148428A patent/TWI518086B/zh not_active IP Right Cessation
-
2012
- 2012-01-11 MY MYPI2013701219A patent/MY164705A/en unknown
- 2012-01-11 EA EA201390823A patent/EA022163B1/ru not_active IP Right Cessation
- 2012-01-11 SG SG2013047311A patent/SG191744A1/en unknown
- 2012-01-11 PT PT127012078T patent/PT2663564E/pt unknown
- 2012-01-11 BR BR112013017672A patent/BR112013017672A2/pt not_active Application Discontinuation
- 2012-01-11 WO PCT/US2012/020897 patent/WO2012097039A1/en active Application Filing
- 2012-01-11 DK DK12701207.8T patent/DK2663564T3/en active
- 2012-01-11 HU HUE12701207A patent/HUE024426T2/en unknown
- 2012-01-11 KR KR1020137018235A patent/KR101561360B1/ko active IP Right Grant
- 2012-01-11 CN CN201280005256.0A patent/CN103282364B/zh not_active Expired - Fee Related
- 2012-01-11 ME MEP-2015-14A patent/ME02019B/me unknown
- 2012-01-11 SI SI201230117T patent/SI2663564T1/sl unknown
- 2012-01-11 JP JP2013549509A patent/JP5891247B2/ja not_active Expired - Fee Related
- 2012-01-11 PL PL12701207T patent/PL2663564T3/pl unknown
- 2012-01-11 EP EP12701207.8A patent/EP2663564B1/en active Active
- 2012-01-11 RS RS20150095A patent/RS53828B1/en unknown
- 2012-01-11 PE PE2013001553A patent/PE20140864A1/es active IP Right Grant
- 2012-01-11 ES ES12701207.8T patent/ES2531891T3/es active Active
- 2012-01-11 MX MX2013008185A patent/MX2013008185A/es active IP Right Grant
- 2012-01-11 CA CA2824760A patent/CA2824760C/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,886 patent/US8440829B2/en not_active Expired - Fee Related
- 2012-01-11 AU AU2012205619A patent/AU2012205619B2/en not_active Ceased
- 2012-11-01 UA UAA201308519A patent/UA109921C2/ru unknown
-
2013
- 2013-04-16 US US13/863,411 patent/US8658668B2/en not_active Expired - Fee Related
- 2013-06-03 TN TNP2013000237A patent/TN2013000237A1/fr unknown
- 2013-06-14 CR CR20130289A patent/CR20130289A/es unknown
- 2013-06-24 IL IL227165A patent/IL227165A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04757A patent/ZA201304757B/en unknown
- 2013-07-01 DO DO2013000158A patent/DOP2013000158A/es unknown
- 2013-07-09 CL CL2013002005A patent/CL2013002005A1/es unknown
- 2013-07-11 GT GT201300180A patent/GT201300180A/es unknown
- 2013-07-12 EC ECSP13012764 patent/ECSP13012764A/es unknown
- 2013-07-12 SV SV2013004496A patent/SV2013004496A/es unknown
- 2013-07-25 CO CO13176485A patent/CO6731133A2/es unknown
-
2014
- 2014-02-19 HK HK14101571.9A patent/HK1188454A1/xx not_active IP Right Cessation
-
2015
- 2015-01-30 CY CY20151100096T patent/CY1116007T1/el unknown
- 2015-02-04 HR HRP20150135AT patent/HRP20150135T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000237A1 (en) | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor | |
PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
TN2009000400A1 (en) | Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha | |
MX2020002150A (es) | Terapia de combinación para el tratamiento del cáncer. | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
MX354509B (es) | Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos. | |
MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
UA117830C2 (uk) | Похідні біпіразолу як інгібітори jak | |
HK1140141A1 (en) | Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
WO2012068106A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
WO2012068096A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
MX359207B (es) | Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo. | |
JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
WO2014160177A3 (en) | Quinazoline inhibitors of pi3k | |
NZ620263A (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor | |
TH149217B (th) | สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้ง คู่สำหรับ Pl3 คิเนส/MTOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |